Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-27
1997-12-16
Jarvis, William R.A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31495
Patent
active
056985584
ABSTRACT:
Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.
REFERENCES:
patent: 4525358 (1985-06-01), Baltes et al.
De Vos & Maleux et al., Ann. Allergy, 59(4), 278-82, 1987. (from Chemical Abstracts -American Chemical Society).
De Vos & Joseph et al., Int. Arch. Allergy Appl. Immunol., 88(1-2), 212-15, 1989. (from Chemical Abstracts).
Gong et al., 90:243620 Biosis, BA89:130573, 1990.
Testa et al. "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?"Chirality,2 129-133 (1990).
Schoeffter et al. "Competative and stereoselective histamine H.sub.1 antagonistic effect . . . " Eur. J. Parmacol., 136, 235-237 (1987).
Fricke et al. "Fortschiritte fur die Arzneimtteltherapie?"Neue Arzneimittel 1990/1991, 14-21 (1991).
Jarvis William R.A.
Sepracor Inc.
LandOfFree
Methods for treating allergic disorders using optically pure (-) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating allergic disorders using optically pure (-), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating allergic disorders using optically pure (-) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-206390